Gilead Sciences engages in the research, development, and commercialized production of biopharmaceutical prescription drugs. The R&D pipeline is highly concentrated on antiviral medications, specifically targeted treatment regimens for HIV and various viral hepatitides; it also ventures into the development of oncology cell therapies and inflammatory disease drugs. The company advances clinical reviews of compounds, primarily supplying approved medications in bulk to pharmacy networks, hospitals, and medical procurement agencies.